EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Myriad Genetics, Inc (0K3W) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Myriad Genetics, Inc $1.46, price $4.29, upside -65.9%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · ISIN US62855J1043

MG Thin data Sep 24, 2026

Myriad Genetics, Inc

0K3W · LSE

Weakest SetupStrongly overvalued and low quality.

!Fair value $1.46 · Strongly overvalued (−65.9%)
!Quality 49/100
!Expensive Growth (revenue 5y +5.2 %/yr)
!Loss-making · -41.3% net margin (TTM)
!negative free cash flow
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$46.38 $2.90 Fair Value $1.46 Apr 2018 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $2.90 – $46.38 · fair‑value band $1.09 – $2.18 · the $4.29 price screens above the $1.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Show more

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Stock analysis

Myriad Genetics, Inc (0K3W) currently trades at $4.29, while our model-based Fair Value estimate is $1.46, 65.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $1.09 (bear) to $2.18 (bull), the price of $4.29 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Myriad Genetics, Inc reported revenue of $825M in FY2025 versus $691M in FY2021, a compound +4.5%/yr. Reported net income was −$366M in FY2025.

Key figures

Market cap $397M · EPS (TTM) $−0.1090 · Net margin −44.4% · Return on equity −23.5% · Return on assets (EBIT) −11.7% · Operating margin −21.4% · Revenue (TTM) $557M · Revenue growth (YoY) −20.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 48% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −66%, 0K3W screens richer than that median.

Fair Value models

Bear $1.09 Fair Value $1.46 Bull $2.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.09 $1.46 $2.18 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.09 $1.46 $2.18 51

Open the full fair value analysis →

Notify me when 0K3W reaches fair value

Put 0K3W on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 51 · Market factors (momentum, volatility) 12

Profitability 38
Margins and returns on capital today
Quality Growth 52
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 6
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 46
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.1% (2020) → −8.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0K3W screens overvalued: fair value 66% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Myriad Genetics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Myriad Genetics, Inc · Fair Value
$1.46 −66%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Myriad Genetics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/0K3W

Frequently asked questions

Is Myriad Genetics, Inc (0K3W) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1.46 versus a price of $4.29, about −66% upside (overvalued).
What is the fair value of 0K3W?
Our model-based fair value for Myriad Genetics, Inc is $1.46 (as of Sep 24, 2026), built from audited fundamentals. The current price: $4.29.
What is the quality score of 0K3W?
Myriad Genetics, Inc has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myriad Genetics, Inc (0K3W)?
Our model-based price target is the fair value of $1.46 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $1.09, optimistic scenario $2.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Myriad Genetics, Inc stock forecast for 2026?
Our models put fair value at $1.46, about −66% upside versus a price of $4.29 (overvalued). Cautious scenario $1.09, optimistic scenario $2.18. The calculation is refreshed regularly with new filings.
What is the revenue of Myriad Genetics, Inc (0K3W)?
Myriad Genetics, Inc reported trailing-twelve-month revenue of about $557M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Myriad Genetics, Inc (0K3W)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myriad Genetics, Inc it is $1.46 per share (as of Sep 24, 2026), against a price of $4.29. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Myriad Genetics, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0K3W trades above its calculated fair value: price $4.29, fair value $1.46, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0K3W?
No. The price is what the market pays today ($4.29); the fair value is what the company's own numbers justify ($1.46). For Myriad Genetics, Inc the two are $2.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Myriad Genetics, Inc worth?
The market values Myriad Genetics, Inc at about $397M (market capitalisation, as of Sep 24, 2026). Per share that is $4.29; our models calculate a fair value of $1.46 per share.
What do the bullish and bearish scenarios say about 0K3W?
Our models span a range for Myriad Genetics, Inc: cautious scenario $1.09, base $1.46, optimistic $2.18 per share (as of Sep 24, 2026, price $4.29). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0K3W from its 52-week high?
Myriad Genetics, Inc trades at $4.29, about 48% below its 52-week high of $8.18 and 48% above the low of $2.90 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.46 is for.
Which stocks are comparable to Myriad Genetics, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myriad Genetics, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $4.29, calculated fair value $1.46 (−66%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0K3W calculated?
We run Myriad Genetics, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Myriad Genetics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myriad Genetics, Inc (0K3W)?
The closing price on Oct 2, 2026 was $4.29. Our model-based fair value is $1.46, about −66% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myriad Genetics, Inc right now?
The price sits above even our optimistic bull case ($2.18). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.09 to $2.18) leaves room in how you read the outcome.

Key figures of Myriad Genetics, Inc

How large is the market capitalisation of Myriad Genetics, Inc (0K3W)?
The market capitalisation of Myriad Genetics, Inc is $397M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Myriad Genetics, Inc (0K3W)?
Earnings per share at Myriad Genetics, Inc are $−0.1090. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Myriad Genetics, Inc (0K3W)?
The net margin of Myriad Genetics, Inc is −44.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myriad Genetics, Inc (0K3W)?
The return on equity (ROE) of Myriad Genetics, Inc is −23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myriad Genetics, Inc (0K3W)?
On an EBIT basis the return on assets of Myriad Genetics, Inc is −11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myriad Genetics, Inc (0K3W)?
The operating margin of Myriad Genetics, Inc is −21.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myriad Genetics, Inc (0K3W)?
Revenue at Myriad Genetics, Inc is growing −20.8% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Myriad Genetics, Inc (0K3W) generate?
The free cash flow of Myriad Genetics, Inc is −$13.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myriad Genetics, Inc (0K3W) carry?
The net debt of Myriad Genetics, Inc is $143M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.